Lorazepam Injection Shortage: Current Availability and Manufacturer Updates

Source: FDA · United States

According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.

The FDA has reported a current shortage of Lorazepam Injection due to increased demand, with supply issues expected to continue through early 2026.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on February 12, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.

For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Lorazepam) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.

What's in Shortage

There is currently a shortage of Lorazepam Injection, a medication within the Neurology therapeutic category. This shortage affects the generic form of the drug as well as products labeled under the brand name LORAZEPAM. The specific dosage form impacted is the injection.

As of the latest update on February 5, 2026, the shortage remains listed as "Current" by the FDA.

Which Manufacturers Are Affected

The following manufacturer has reported availability issues:

  • Fresenius Kabi USA, LLC
    • Status: Unavailable
    • Presentation: Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)
    • Notes: The manufacturer estimates the next release of this product will be in March 2026.
    • Contact Information: 888-386-1300

Why There's a Shortage

According to the FDA database, the reason for this shortage is a demand increase for the drug. This shortage was first posted on May 3, 2018, and has been subject to ongoing monitoring.

What Patients Should Do

If you or a loved one are prescribed Lorazepam Injection, please consider the following steps:

  • Consult Your Healthcare Provider: Speak with your doctor or specialist about how this shortage may affect your treatment plan.
  • Speak with a Pharmacist: Your pharmacist can provide the most current information on local availability and stock levels.
  • Contact the Manufacturer: You may reach out to Fresenius Kabi USA, LLC at 888-386-1300 for specific inquiries regarding their supply timeline.
  • Inquire About Alternatives: Ask your healthcare provider if there are suitable alternative medications or different dosage forms available during this period.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should always consult with their healthcare provider or pharmacist regarding medication changes or treatment options.

Source

This information is based on data from the FDA Drug Shortage Database. Initial Posting Date: 05/03/2018
Last Updated: 02/05/2026

Original source: FDA Official Notice ↗

All Drug Shortages →

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
The FDA has reported a current shortage of Lorazepam Injection due to increased demand, with supply issues expected to continue through early 2026.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.